Novel tests for heart failure can better guide the diagnosis and ongoing care of heart failure, which could reduce deaths and re-hospitalizations, according to a scientific statement published recently by the American Heart Association (AHA).
Western University of Health Sciences College of Pharmacy Associate Professor Sheryl Chow, PharmD, FCCP, FAHA, FHFSA, BCPS-AQ Cardiology, was lead author on the AHA scientific statement, which took two years of work and brought together providers from pharmacy and the medical community to change current thinking.
The noninvasive blood or urine tests measure biomarkers, which are substances released by the body during heart failure, a complex condition involving several body processes. This includes the response to inflammation, the death of heart cells, and the restructuring of the heart, according to an AHA news release.
Chow SL (Chair), Maisel A (Vice-Chair), Anand I, Bozkurt B, De Boer, R, Greenberg B, Felker M, Januzzi J, Kiernan M, Fonarow G, Liu P, Wang T, Yancy CW, Zile MR. AHA Scientific Statement: The Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement from the American Heart Association. American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. [Epub ahead of print] Circulation. March 26, 2017.
Click here to read the scientific article: http://circ.ahajournals.org/content/early/2017/04/26/CIR.0000000000000490
Click here to view a news release from the American Heart Association that includes quotes from Dr. Chow: http://news.heart.org/new-guidance-on-heart-failure-tests-can-improve-care/.